OncoMatch/Clinical Trials/NCT05739045
Nivolumab Combined With SOX Used in the Perioperative Treatment
Is NCT05739045 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies nivolumab combined with SOX for immune suppression.
Treatment: nivolumab combined with SOX — To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT3-4 (AJCC version 8)
clinical staging of cT3-4 or N+, M0 (staging according to AJCC version 8) who could be radically resected as determined by CT and laparoscopy
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥80×10^9/L; Hemoglobin ≥ 80 g/L
Kidney function
Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance > 50 ml/min
Liver function
Total bilirubin <1.5×ULN; ALT and AST≤2.5×ULN
Main organ functions normal, i.e., meeting the criteria below: (No blood transfusion or blood products within 14 days, no G-CSF or other hematopoietic stimulating factors are used for correction) Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥80×10^9/L; Hemoglobin ≥ 80 g/L; Total bilirubin <1.5×ULN; ALT and AST≤2.5×ULN; Serum Cr ≤ 1.5 × ULN or endogenous creatinine clearance > 50 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05739045 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT3-4 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages